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Resting peripheral blood mononuclear cells (PBMC) or purified T-cells can be induced to proliferate when cocultured in
vitro with fixed HTLV-infected T-cells. This process of HTLV-dependent cellular activation and induction of proliferation has
been considered distinctive because of an apparent independence from conventional T-cell costimulatory signals. We have
examined several HTLV-infected cell lines and found that proliferation was readily induced in resting PBMC by T-cells that
were productively-infected with HTLV. However, equivalent HTLV-productive infection in a B-cell line failed to induce prolifera-
tion in PBMC, suggesting that HTLV-dependent induction of proliferation in PBMC was, at least in part, dependent upon a
T-cell-specific signal. Furthermore, the induction of proliferation in PBMC populations was found to overlap with, and actually
require, transfer and establishment of HTLV infection within the T-cell compartment of the PBMC population. These findings
suggest that virus-induced activation of target cells may be directly associated with transfer and spread of HTLV infection.
q 1996 Academic Press, Inc.
HTLV-infected T-cells can cause direct activation of DNA cannot integrate and support viral transcription un-
less the infected cell progresses through the cell cyclepurified T-cells, or resting PBMC, in the absence of ac-
cessory cells (1 – 4). This system has been studied under into S phase (8, 9). The mitogenic activation of resting
T-cells/PBMC by HTLV-I-infected T cells is widely recog-the premise that in vitro cell–cell interactions may have
some bearing on pathogenic processes induced by nized (1–5) as is T-cell immortalization by HTLV-I (10–
12), but the connection between these two events, in theHTLV-I in seropositive individuals. Antibodies directed
against HTLV proteins, including gp46, the external gly- early stages of an interaction between HTLV-infected and
uninfected cells, has not been fully explored. By selectingcoprotein, have generally not been effective in preventing
the activation of responder cells (4, 5), suggesting that mixed PBMC populations as responder cells, we sought
to retain the complexity of cell types that may participatesurface expression of HTLV proteins on the effector cells
may be a surrogate marker for activation rather than a in the initiation, and subsequent maintenance, of HTLV
infection in seropositive individuals.trigger for activation. The cell surface ligand/receptor
pair, LFA-3/CD2, is known to be required for the HTLV- Paraformaldehyde-fixed HTLV-I-infected T-cell lines,
MT-2, OS-P2 and HUT-102, induced proliferation in aassociated activation (4–6). However, it is not clear at
present whether the LFA-3/CD2 interaction is solely facil- mixed population of resting PBMC (Table 1) in a standard
proliferation assay (5). There was no proliferative re-itating adhesion between the effector HTLV-I-infected
cell and the responder cell and/or whether an activation sponse if the PBMC were cultured either alone or in the
presence of the uninfected T-cell line, Jurkat. However,signal is being transmitted through CD2 on the responder
cell. Signaling through cell surface molecules is likely addition of PHA to the mixed cultures induced a strong
proliferative response in all cases (Table 1). The HTLV-to be involved with HTLV-induced proliferation because
HTLV-I-infected T-cells show extensive change in the I-infected T-cell lines that were capable of inducing a
proliferative response in resting PBMC have been char-surface profile of cellular receptors (7).
In this study, we examined whether HTLV-induced acti- acterized as virus producers. These T-cell lines all dis-
played significant FACS surface staining for the majorvation of resting lymphocytes could be linked to the trans-
fer of virus infection. Unlike HIV-1, HTLV-I and -II proviral HTLV-I external glycoprotein, gp46, and readily formed
syncytia with HOS indicator cells (13) (Table 1). In con-
trast, the HTLV-I nonproducer cell line, C8166-45, did1 To whom correspondence and reprint requests should be ad-
not induce measurable proliferation in the resting PBMCdressed at Department of Microbiology, University of Minnesota, Box
population, as has been reported previously (1), did not196 UMHC, 420 Delaware St., SE, Minneapolis, MN 55455. Fax: 612-
626-0623. show surface staining for gp46 expression, and failed to
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TABLE 1
Characterization of HTLV-I-Infected Cell Lines
Induction of proliferation in resting PBMC Status of HTLV-I infection
Donor 1a Donor 1a Donor 2a gp46 Syncytium
Cell line (%) (%) (%) expressionb formationc
MT-2 100.0 100.0 100.0 / /
OS-P2 125.0 140.0 48.0 / /
C8166-45 2.0 3.9 1.4 0 0
U937/HTLV-I 0.5 0.3 0.2 (/) (//0)
HUT-102 ND ND 76.0 / /
Jurkat 0.2 0.3 2.2 0 ND
Jkt-HTLV 0.6 0.5 0.5 0 0
Jkt-HTLVd 0.3 0.3 ND 0 ND
PBMC, unstimulated 0.8 0.5 1.2 ND ND
PBMC / PHA (1 mg/ml) 134.0 152.0 98.0 ND ND
Note. ND, not determined.
HTLV-I-infected cells: MT-2, an HTLV-I producer CD4/ T-cell line, derived by cocultivation of umbilical cord lymphocytes with leukemic cells from
an ATL patient (10). MT-2 cells were kindly provided by Dr. Masataka Nakamura, Tohoku University School of Medicine, Japan.
HUT-102, an HTLV-I producer CD4/ T-cell line, derived from a lymph node biopsy of a patient with mycosis fungoides (27, 28), was obtained
from ATCC.
OS-P2/HTLV-I, an HTLV-I producer CD8/ T-cell line, derived by cocultivation of normal PBMC with cerebrospinal fluid from a HAM/TSP patient
(29, 30). OS-P2/HTLV-I cells were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr.
Michael D. Lairmore.
C8166-45, an HTLV-I nonproducer CD4/ T-cell line, derived by cocultivation of umbilical cord lymphocytes with CRII HTLV-I-infected T-cells (31).
C8166-45 cells contain several copies of defective HTLV-I proviruses and synthesize no viral proteins with the exception of Tax. C8166-45 cells
were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Robert Gallo.
Uninfected/control cells; Jurkat T-cells and U937 histiocytic/monocytic cells were kindly provided by Dr. R. Guntaka, University of Missouri. HTLV-
I infections were established in Jurkat and U-937 cells by cocultivation with mitomycin-C-treated MT-2 cells. HTLV-I-infected Jurkat clones (Jkt-HTLV)
were obtained by limiting dilution cloning. The HTLV-I-infected U-937 cells (U937/HTLV-I) were maintained as an uncloned cell population.
Proliferation assays; PBMC were purified by centrifugation over Histopaque-1077 (Sigma), starting with heparinized blood from normal healthy
donors. HTLV-I-infected cells (5 1 106 –1 1 107 cells/ml) were fixed in 2% paraformaldehyde/PBS solutions for 1 hr at 377 and were then washed
three times in PBS to remove residual paraformaldehyde. Freshly purified PBMC were mixed with freshly fixed HTLV-1-infected cells, or fixed control
cells, in 96-well plates, 105 cells of each type per well. As a control for PBMC viability and induction of proliferation, phytohemagglutinin (1 mg/ml
PHA, Sigma) was added, as indicated. At designated times between Days 4 and 8 after initiation of the mixed cultures, 1 mCi[3H]thymidine (NEN
Research Products) was added to individual wells and the cells were harvested 12 hr later for liquid scintillation counting. In any given assay, all
experimental combinations were performed in triplicate.
a For ease of comparison, the proliferation induced by MT-2 in each experiment was set at 100% and all results are shown as a percentage of
the MT-2 value. Two experiments were performed with PBMC prepared from Donor 1 on separate days. The mean values for [3H]thymidine
incorporation (cpm) induced by MT-2 were 88,590 and 71,089 in the two experiments. A third experiment with PBMC from Donor 2 gave a mean
value for MT-2 proliferation of 60,427.
b Surface expression of gp46 was assessed by FACS. The fluorescence intensity for U937/HTLV-I indicated positive staining but at reduced levels
relative to MT-2, OS-P2, and HUT-102.
c Syncytium formation was assessed by coculture with HOS cells.
d Jkt-HTLV cells were treated with PHA and IL-2 for 7 days before being used as effector cells in these proliferation assays.
induce syncytia with HOS cells (Table 1). These results PBMC, this comparison is less than optimal for biochemi-
cal analysis of HTLV-induced changes. To improve thecollectively suggested that viral proteins were directly
involved in the mitogenic activation and/or that active match between HTLV-infected and uninfected control
cells, we attempted to establish HTLV-I infections in Jur-synthesis and accumulation of viral proteins correlated
with virus-induced changes in cellular products and that kat T-cells and the human histiocytic cell line, U937. Anal-
ysis of single cell clones derived from coculture of Jurkataltered cellular products were directly involved with the
mitogenic activation. cells with mitomycin-C-treated MT-2 cells revealed the
presence of HTLV-I proviral DNA but no evidence forOne limitation with the existing HTLV-infected cell
lines arises from the absence of well-matched, unin- proviral transcription or synthesis of viral proteins (RT-
PCR amplifications and FACS, data not shown). The Jur-fected control cells. The Jurkat T-cell line has been used
as an uninfected control for comparison with the HTLV- kat/HTLV-I clones were not mitogenic to resting PBMC
and failed to induce syncytia with HOS cells (Table 1).I-infected cord-derived MT-2 cells (3, 5) and, although
uninfected Jurkat cells are nonmitogenic to resting These properties could not be altered by stimulating the
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TABLE 2
Characterization of HTLV-II-Infected Cell Lines
Induction of Proliferation Status of HTLV-II infection
in Resting PBMC
Donor 1a Donor 2a
Cell line (%) (%) gp46 expressionb Syncytium formationc
MT-2 100.0 100.0 / /
Mo 38.0 85.0 / ND
Mo-B 0.5 1.4 / /
pH6neo ND ND / /
DAUDI 0.3 0.9 0 0
PBMC, unstimulated 0.4 1.1 0 ND
PBMC / PHA (1 mg/ml) 178 214.0 0 ND
Note. HTLV-II-infected cells: Mo, an HTLV-II producer CD4/ T-cell line, derived by outgrowth of leukemic cells from a patient with hairy cell
leukemia (17).
Mo-B, an HTLV-II producer B-cell line, derived by EBV transformation of B-cells from the same patient source as Mo (16). The Mo and Mo-B cells
were obtained from ATCC.
pH6neo, an HTLV-II producer CD4/ T-cell line, derived by cocultivation of PBLs with a B cell line that had been stably transfected with a cloned
infectious HTLV-II provirus (32). This cell line was kindly provided by Dr. Irvin Chen, UCLA.
Control cells: The EBV-transformed B-cell line, DAUDI, was obtained from ATCC.
a For ease of comparison, the proliferation induced by the MT-2 was set at 100% and all results are shown as percentages of MT-2 value.
[3H]Thymidine incorporation (cpm) induced by MT-2 (mean of triplicate cultures): Donor 1  59,203 and Donor 2  16,566.
b Surface expression of gp46 was assessed by FACS with MAb specific for either HTLV-1 or HTLV-II gp46.
c Syncytium formation was assessed by coculture with HOS cells.
Jurkat/HTLV-I clones with PHA, under conditions that have infected with HTLV-I or HTLV-II. Unfortunately, there is a
relative paucity of appropriate HTLV-infected non-T-cellbeen shown to induce transcription from the HIV-1 LTR in
Jurkat cells (14). Analysis of the cell population growing lines. HTLV-I infection has been established in HOS cells
(15) but these cells lack detectable LFA-3 expression (5)out of a coculture of U937 cells with mitomycin-C-treated
MT-2 cells revealed the presence of HTLV-I proviral DNA and therefore cannot establish the LFA-3/CD2 interaction,
which is known to be essential for mitogenic activation (6).and a positive signal by RT-PCR for proviral transcription
(data not shown). FACS analysis indicated that approxi- The HTLV-II-infected B-cell line, Mo-B (16), did appear to
be suitable for our purpose, especially since direct compari-mately 60% of the cell population expressed gp46 at the
cell surface but the fluorescence intensity of the gp46 sons would be possible with the HTLV-II-infected T-cell
line, Mo (17). (The Mo-B and Mo cell lines were establishedsignal from U937/HTLV-I cells was about 10-fold lower
than that observed with MT-2 cells (U937/HTLV-I: peak as outgrowths of cells from the same HTLV-II-infected indi-
vidual.) Mo-B cells showed strong staining for surface ex-channel fluorescence 35.5 and 63% positive cells; MT-2:
peak channel fluorescence 291.6 and 92% positive cells). pression of HTLV-II gp46 and induced syncytia efficiently
with the HOS indicator cells. However, in the standard mito-Both uninfected U937 and U937/HTLV-I expressed high
levels of surface LFA-3 but the U937/HTLV-I cells were not genicity assay, Mo-B cells failed to induce proliferation in
resting PBMC, whereas there was a marked proliferativeconsistently mitogenic to resting PBMC. At best, thymidine
counts for U937/HTLV-I were no more than 5–10% of the response induced by Mo T-cells (Table 2). These findings
suggest that there are components on the surface of pro-MT-2 counts in any given proliferation assay and syncy-
tium formation was observed only occasionally between ductively infected T-cells that are required for the mitogenic
activation and that equivalent, HTLV-induced changes doU937/HTLV-I cells and HOS cells (Table 1). These findings
suggested either that the levels of HTLV-I expression in not occur in the Mo-B cells.
In the process of analyzing mixtures of PBMC andthe U937 cells were insufficient to induce the appropriate
signals for mitogenic activation of the resting PBMC and/ paraformaldehyde-fixed MT-2 cells, we noticed a time-
dependent increase in numbers of cells that stained posi-or that U937/HTLV-I, as a non-T-cell, lacked essential,
virus-induced signals that were necessary to trigger mito- tively for HTLV-I gp46 surface expression (Fig. 1). This
staining could not be explained by the presence of resid-genic activation.
In light of the findings for the U937/HTLV-I cells, it was ual MT-2 cells and suggested that transfer of HTLV-I
infection was occurring to constituent cells in the PBMCof considerable interest to resolve whether the property
of mitogenic activation was unique to T-cells productively population. Transfer of infection would not have been
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FIG. 1. Surface expression of gp46 as an indicator of time-dependent transfer and establishment of HTLV-I infection in PBMC. Samples were
removed as indicated from mixed cocultures of PBMC with fixed MT-2 cells, centrifuged over Ficoll gradients to recover viable cells, and then
stained with anti-SP2, 3/4A, a goat polyclonal anti-peptide antiserum, to detect surface expression of HTLV-I gp46 by FACS. Antiserum to HTLV-I
SP-2, 3/4A was obtained through the AIDS Research and Reference Program, Division of AIDS, NIAID, NIH, and was provided by Dr. Thomas Palker
(26). For FACS staining with 106 cells, 5 ml of a 1:100 dilution of the SP-2, 3/4A antiserum was used, followed by R-PE-conjugated rabbit anti-goat
immunoglobulins (Zymed). The solid profiles indicate the specific staining pattern and the unshaded profiles indicate background staining obtained
with a matched, unrelated primary antibody. The upper right panel shows representative staining for MT-2 cells with the anti-SP2, 3/4A antiserum.
anticipated based on the paraformaldehyde fixation pro- paraformaldehyde for 30–60 min could be expected to
leave some HTLV-I infectivity intact. This new insightcedure used with the MT-2 cells (5) but we then became
aware of an independent study that had systematically then immediately led to a critical question of whether the
transfer of HTLV-I infection was causal to the prolifera-analyzed paraformaldehyde inactivation conditions (18)
and realized that standard fixation conditions of 1–2% tion of the responding PBMC or whether, following mito-
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(19, 20), to determine the infection status of distinct cell
types in the proliferating PBMC populations (Fig. 2). Ap-
proximately 19% of the proliferating cells were scored as
infected and included 13% CD4/ and 5% CD8/ T-cells.
The discrepancy between the numbers of proliferating
cells and HTLV-I-infected cells could indicate either a
substantial underestimation of the number of infected
FIG. 2. Identification of specific cell types within the population of
HTLV-I-infected proliferating cells. Proliferating cells were labeled by
incorporation of BrdU (19, 20) and FACS analysis was performed by
gating on BrdU-positive cells. Double labeling was performed to detect
gp46 (anti SP2, 3/4A, see legend to Fig. 1) in combination with CD4,
CD8, or CD19. [Antibodies used: FITC-conjugated mouse anti-human
CD4 and FITC-conjugated mouse anti-human CD8 (Pharmingen), FITC-
conjugated mouse anti-human CD19 (Sigma)]. The distribution of cells
for each quadrant (%) is indicated adjacent to the two-dimensional
staining profiles.
FIG. 3. Inhibitors of HTLV-I replication block the establishment ofgenic activation, the transfer of HTLV-I occurred as a
HTLV-I infection in PBMC. Cells from cocultures were stained with anti-secondary event.
SP2, 3/4A (see legend to Fig. 1) and analyzed by FACS to detect surface
We established a correlation between cell proliferation expression of HTLV-I gp46. The solid profiles indicate the specific
and HTLV-I infection using a triple-label FACS staining staining pattern and the unshaded profiles indicate background stain-
ing obtained with a matched, unrelated primary antibody.procedure, based on BrdU labeling of cells in S phase
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TABLE 3
Nucleoside Analogs Inhibit HTLV-Induced Proliferation in Resting PBMC
Donor 1a Donor 2a
PBMC / MT-2 PBMC / pH6neo PBMC / PHA PBMC / MT-2 PBMC / pH6neo PBMC / PHA
Inhibitor (%) (%) (%) (%) (%) (%)
None 100.0 100.0 100.0 100.0 100.0 100.0
AZT (10 mM) 0.9 9.5 51.6 0.8 23.2 31.7
ddC (2 mM) 3.6 1.3 90.4 1.4 1.4 93.3
a For ease of comparison, the proliferation induced by the MT-2, pH6neo, and PHA positive controls was set at 100% and other results are shown
as percentages of those values. [3H]Thymidine incorporation (cpm): Donor 1 MT-2  95,781; pH6neo  40,350; PHA (1 mg/ml)  35,697; Donor 2
MT-2  56,332; pHG6neo  39,972; PHA (1 mg/ml)  10,228.
cells, by lack of sensitivity of detection, and/or induction we did not obtain lines capable of inducing the HTLV-I-
dependent activation process. This could easily be ex-of proliferation of uninfected cells by bystander activa-
tion. For example, the effective absence of infected B- plained for the Jurkat/HTLV-I cells that did not transcribe
the integrated HTLV-I proviral DNA. The situation wascells (0.68% of the proliferating cell population) and the
detection of 31% B-cells in the proliferating population more complex for the U937/HTLV-I cells because provi-
rus transcription did occur and surface accumulation ofwere fully compatible with a process of bystander activa-
tion. gp46 was detectable, albeit at reduced levels relative to
MT-2 or other productively infected T-cell lines. The fail-In the final series of experiments, we used inhibitors
of HTLV-I replication (21) to resolve whether the induction ure of U937/HTLV-I cells to induce proliferation in resting
PBMC could reflect either an insufficiency of virus-in-of proliferation in the PBMC population was primarily
dependent upon the transfer of HTLV-I infection. When duced change and/or an absence of signals from the
U937 histiocytic cells that are normally provided by HTLV-cocultures were incubated in the presence of the nucleo-
side analogs, AZT or ddC, there was a dramatic reduction infected T-cells. Experiments performed with Mo-B cells,
a B-cell line productively infected with HTLV-II (16), pro-in the induced proliferative responses for two different
PBMC populations (Table 3). In particular, with ddC, vided a clear indication of the relative importance of the
parameters under study. Surface expression of gp46 wasHTLV-I-induced proliferation was reduced to only 4% of
the intact control and, as shown from a comparison of approximately the same on Mo-B cells and the produc-
tively infected T-cell lines and Mo-B cells formed syncytiaPHA-induced proliferation in the presence or absence of
ddC, there was essentially no cytotoxic effect from the readily with HOS indicator cells but the Mo-B cells failed
to induce proliferation of resting PBMC. These observa-drug. In contrast, the reduction of PHA-induced prolifera-
tion in the presence of AZT was indicative of drug-in- tions argue strongly for the requirement of a T-cell-spe-
cific signal as an essential component of the HTLV-I-duced cytotoxicity but an inhibitory effect on HTLV-I-as-
sociated proliferation was still readily apparent. A similar dependent proliferative response.
Activation of CD4/ T-cells is normally dependent uponinhibition of HTLV-II-associated proliferation was ob-
served when the nucleoside analogs were added to receipt of two-signals: (i) delivered through the T-cell
antigen receptor (TCR) and (ii) delivered through a costi-mixed cultures containing fixed pH6neo cells (Table 3).
Both inhibitors were also effective in preventing the es- mulatory receptor, for example CD28 (22). Both signals
must act in concert because, without costimulation, sig-tablishment of HTLV-I infection in the PBMC population,
as deduced from an absence of surface gp46 staining naling through the TCR will result in anergy rather than
activation. The only known exception to this general situ-at Day 7 (Fig. 3). Furthermore, because proliferation in
the presence of the inhibitors was effectively reduced to ation occurs with superantigens which bind to an exter-
nal portion of the MHC class II/TCR complex, away frombackground levels, this argues that bystander activation
of uninfected cells in the PBMC population must occur the peptide-binding groove, and induce activation of TCR-
specific subsets of T-cells in the absence of costimula-and is secondary to HTLV-induced proliferation.
We have identified a correlation between HTLV-depen- tion (23). Recent studies have demonstrated that CD80,
the ligand for the costimulatory CD28 molecule, can bedent induction of proliferation in resting PBMC and syn-
cytium formation and surface expression of HTLV gp46 expressed on T-cells and participate in T-cell-dependent
activation of T-cells (24). Furthermore, Dezzutti et al. (7)on HTLV-infected effector T-cells. In an attempt to create
additional cell lines infected by HTLV-I, we introduced have observed that surface expression of CD80 is in-
duced in HTLV-I- and -II-infected T-cell lines and haveHTLV-I into Jurkat and U937 cells by cocultivation, but
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